The United States Food and Drug Administration (FDA) has granted approval to United States-based Pfizer for the subcutaneous use of Fragmin (dalteparin sodium) injection intended for the treatment of potentially life-threatening blood clots in paediatric patients, it was reported on Friday.
The latest approval for the product is for the blood thinner to be used to decrease symptomatic venous thromboembolism in paediatric patients, aged one month and older.
Its efficacy in children was demonstrated in a single trial with 38 paediatric patients having symptomatic deep vein thrombosis and/or pulmonary embolism. In the trial, patients were subjected to the product for up to three months, with starting doses based on age and weight. After completion of the study, 21 patients achieved resolution of the qualifying venous thromboembolism, while seven patients had regression. Two patients did not show any change, while no patients had progression of the venous thromboembolism and one patient had recurrence of the condition.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial